

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Sudhir V. Shah

Divisional  
Application No.: 09/553,496 Group Art Unit: 1654

Filed: April 20, 2000 Examiner: Randall O. Winston

Confirmation No.:

Title: DIAGNOSIS AND TREATMENT OF HUMAN KIDNEY DISEASES

Date: 12/9/03

EXPRESS MAIL LABEL NO. EL 955641122 US

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

This Information Disclosure Statement is submitted:

under 37 CFR 1.129(a), or

(First/Second submission after Final Rejection)

under 37 CFR 1.97(b), or

(Within any one of the following time periods: three months of filing national application (other than a CPA) or date of entry of the national stage in an international application; or before the mailing date of a first office action on the merits in a non-provisional application, including a CPA, or a Request for Continued Examination).

under 37 CFR 1.97(c) together with either:

a Statement under 37 CFR 1.97(e), as checked below, or

a \$180.00 fee under 37 CFR 1.17(p), or

(After the 37 CFR 1.97(b) time period, but before final action or notice of allowance, whichever occurs first)

under 37 CFR 1.97(d) together with:

a Statement under 37 CFR 1.97(e), as checked below, and

a \$180.00 fee under 37 CFR 1.17(p), or

(Filed after final action or notice of allowance, whichever occurs first, but on or before payment of the issue fee)

under 37 CFR 1.97(i):

Applicant requests that the IDS and cited reference(s) be placed in the application filewrapper.  
(Filed after payment of issue fee)

Statement Under 37 CFR 1.97(e)

- Each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement; or
- No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned, after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of this Information Disclosure Statement.

Statement Under 37 CFR 1.704(d) (Patent Term Adjustment)

Applies to original applications (other than design) filed on or after May 29, 2000

- Each item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart application and this communication was not received by any individual designated in § 1.56(c) more than thirty days prior to the filing of the Information Disclosure Statement.

Enclosed herewith is form PTO-1449:

- Copies of the cited references are enclosed.
  - Since this application was filed after June 30, 2003, copies of issued U.S. patents and published U.S. applications are not required and are not being provided.
- Copies of the cited references are enclosed except those entered in prior application, U.S. Application No. 09/553,496, to which priority under 35 U.S.C. 120 is claimed. The earlier application contains copies of the cited references.
- The listed references, AL-AO, AY3, AZ3 and AR4, were cited in the International Search Report in a related foreign application, a copy of which was entered in prior Application No. 09/553,496.
- The "concise explanation" requirement (non-English references) for reference AO under 37 CFR 1.98(a)(3) is satisfied by:
  - the explanation provided on the attached sheet.
  - the explanation provided in the Specification.
  - submission of the enclosed International Search Report.
  - submission of the enclosed English-language version of a foreign Search Report and/or foreign Office Action.
- the English language abstract, a copy of which was entered in prior Application No. 09/553,496.

[ X ] Applicant requests that the following non-published pending applications be considered:

Examiner's  
Initials

U.S. Patent Application No. 09/553,496, by Sudhir V. Shah, filed April 20, 2000, Docket No.: 2629.1003-003.

U.S. Patent Application No. [ ], by [inventor(s)], filed [ ], Docket No.: [ ]

U.S. Patent Application No. [ ], by [inventor(s)], filed [ ], Docket No.: [ ]

Examiner

Date

[ ] A copy of each above-cited application, including the current claims, is enclosed.

[ X ] A copy of each above-cited application, including the current claims, is enclosed, except those entered in prior application, U.S. Application No. 09/553,496, to which priority under 35 U.S.C. 120 or 121 is claimed.

The Examiner is requested to return a copy of the above list of pending applications indicating which references were considered with the next office communication.

It is requested that the information disclosed herein be made of record in this application.

Method of payment:

[ ] A check for the fee noted above is enclosed, or the fee has been included in the check with the accompanying Reply. A copy of this Statement is enclosed.

[ ] Please charge Deposit Account 08-0380 in the amount of \$[ ]. A copy of this Statement is enclosed.

[X] Please charge any deficiency in fees and credit any overpayment to Deposit Account 08-0380.

Respectfully submitted,

HAMILTON, BROOK, SMITH & REYNOLDS, P.C.

By Mary K. Murray  
Mary K. Murray  
Registration No.: 47,813  
Telephone: (978) 341-0036  
Facsimile: (978) 341-0136

Concord, MA 01742-9133  
Dated: December 9, 2003

PTO-1449 REPRODUCED			ATTORNEY DOCKET NO. 2629.1003-010	DIVISIONAL APPLICATION NO. 09/553,496	
INFORMATION DISCLOSURE CITATION IN AN APPLICATION			APPLICANT Sudhir V. Shah		
November 14, 2003  (Use several sheets if necessary)			FILING DATE	CONFIRMATION NO.	GROUP 1654

## U.S. PATENT DOCUMENTS

EXAM- INER INI- TIAL	REF. NO.	DOCUMENT NUMBER	ISSUE DATE / PUBLICATION DATE	NAME
	AA	5,047,421	Sep 10, 1991	Green
	AB	5,721,209	Feb 24, 1998	Horwitz <i>et al.</i>
	AC	5,811,127	Sep 22, 1998	Milstein <i>et al.</i>
	AD	4,684,482	Aug 4, 1987	Green
	AE			
	AF			
	AG			
	AH			
	AI			
	AJ			
	AK			
	AA2			
	AB2			
	AC2			
	AD2			
	AE2			
	AF2			
	AG2			
	AH2			
	AI2			
	AJ2			
	AK2			
	AA3			
	AB3			
	AC3			

EXAMINER	DATE CONSIDERED
----------	-----------------

PTO-1449 REPRODUCED  <b>INFORMATION DISCLOSURE CITATION IN AN APPLICATION</b>  November 14, 2003  (Use several sheets if necessary)		ATTORNEY DOCKET NO. 2629.1003-010	DIVISIONAL APPLICATION NO. 09/553,496
		APPLICANT Sudhir V. Shah	
		FILING DATE	CONFIRMATION NO.
			GROUP 1654

FOREIGN PATENT DOCUMENTS					
		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION YES      NO
	AL	WO 94/01770 A	20 Jan 94	PCT	X
	AM	DE 40 08 323 A	19 Sept 91	Germany	X
	AN	WO 00 13706 A	16 Mar 00	PCT (English)	
	AO	WO 91 07956 A	13 June 91	PCT	
	AP				
	AQ				
	AL2				
	AM2				
	AN2				
	AO2				
	AP2				
	AQ2				
	AL3				
	AM3				
	AN3				
	AO3				
	AP3				
	AQ3				
	AL4				
	AM4				
	AN4				
	AO4				
	AP4				
	AO4				
	AL5				
	AM5				

EXAMINER	DATE CONSIDERED
----------	-----------------

PTO-1449 REPRODUCED  <b>INFORMATION DISCLOSURE CITATION IN AN APPLICATION</b>  November 14, 2003  (Use several sheets if necessary)		ATTORNEY DOCKET NO. 2629.1003-010	DIVISIONAL APPLICATION NO. 09/553,496
		APPLICANT Sudhir V. Shah	
		FILING DATE	CONFIRMATION NO. GROUP 1654

OTHER DOCUMENTS ( <i>Including Author, Title, Date, Pertinent Pages, Etc.</i> )			
AR	Sumboonnanonda, A., <i>et al.</i> , "Renal tubular function in $\beta$ -thalassemia", <i>Pediatr Nephrol</i> , 12:280-283.		
AS	Ong-ajyooth, L., <i>et al.</i> , "Renal Function in Adult Beta-Thalassemia/Hb E Disease", <i>Nephron</i> , 78:156-161 (1998).		
AT	Guasch, A., <i>et al.</i> , "Evidence that Microdeletions in the $\alpha$ Globin Gene Protect Against the Development of Sickle Cell Glomerulopathy in Humans", <i>J Am Soc Nephrol</i> , 10:1014-1019 (1999).		
AU	Loebstein, R., <i>et al.</i> , "Diabetic Nephropathy in Hypertransfused Patients with $\beta$ -Thalassemia", <i>Diabetes Care</i> , 21(8):1306-1309 (1998).		
AV	Ongajyooth, L., <i>et al.</i> , "Glomerulonephritis in $\beta$ -thalassemia Hb-E Disease: Clinical Manifestations, Histopathologic Studies and Outcome", <i>J Med Assoc Thai</i> , 78(3):119-126 (1995).		
AW	Aoki, R.Y., <i>et al.</i> , "Microalbuminuria in Sickle Cell Disease", <i>Brazilian J Med Biol Res</i> , 23:1103-1106 (1990).		
AX	Katopodis, K.P., <i>et al.</i> , "Renal Abnormalities in Patients with Sickle Cell-Beta Thalassemia", <i>Journal of Nephrology</i> , 10(3):163-167 (1997).		
AY	Pham, P.-T.T., <i>et al.</i> , "Renal abnormalities in sickle cell disease", <i>Kidney International</i> , 57:1-8 (2000).		
AZ	Kontoghiorghes, G.J., <i>et al.</i> , "Simple Synthesis of the Potent Iron Chelators 1-Alkyl-3-hydroxy-2-methylpyrid-4-ones", <i>Inorganica Chimica Acta</i> , 136:L11-L12 (1987).		
AR2	Falk, R.J., <i>et al.</i> , "Prevalence and Pathologic Features of Sickle Cell Nephropathy and Response to Inhibition of Angiotensin-Converting Enzyme", <i>The New England Journal of Medicine</i> , 326(14):910-915 (1992).		
AS2	Guasch, A., <i>et al.</i> , "Sickle cell anemia causes a distinct pattern of glomerular dysfunction", <i>Kidney International</i> , 51:826-833 (1997).		
AT2	Cianciulli, P., <i>et al.</i> , "Early detection of nephrotoxic effects in thalassemic patients receiving desferrioxamine therapy", <i>Kidney International</i> , 46:467-470 (1994).		
AU2	Ueda, N., <i>et al.</i> , "Role of 'catalytic' iron in an animal model of minimal change nephrotic syndrome", <i>Kidney International</i> , 49:370-373 (1996).		

EXAMINER	DATE CONSIDERED
----------	-----------------

PTO-1449 REPRODUCED  <b>INFORMATION DISCLOSURE CITATION IN AN APPLICATION</b>  November 14, 2003  (Use several sheets if necessary)	ATTORNEY DOCKET NO. 2629.1003-010	DIVISIONAL APPLICATION NO. 09/553,496
	APPLICANT Sudhir V. Shah	
	FILING DATE	CONFIRMATION NO. GROUP 1654

**OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)**

AV2	Savill, J., <i>et al.</i> , "Mechanisms of glomerular injury". In "Oxford Textbook of Clinical Nephrology," 2 <sup>nd</sup> ed., pages 404-439, eds., Davidson, A.M., <i>et al.</i> , Oxford Univ. Press (1998).
AW2	Ueda, N., <i>et al.</i> , "In Vivo Evidence for a Role of Reactive Oxygen Metabolites in Glomerular Disease", <i>Kidney: A Current Survey of World Literature</i> , 6:143-146 (1997).
AX2	Boyce, N.W., <i>et al.</i> , "Hydroxyl radical mediation of immune renal injury by desferrioxamine", <i>Kidney International</i> , 30:813-817 (1986).
AY2	Baliga, R., <i>et al.</i> , "Kidney Iron Status in Passive Heymann Nephritis and the Effect of an Iron-Deficient Diet", <i>J Am Soc Nephrol</i> , 7(8):1183-1188 (1996).
AZ2	Shah, S.V., "Evidence suggesting a role for hydroxyl radical in passive Heymann nephritis in rats", <i>The American Physiological Society</i> , F337-F344(1988).
AR3	Thakur, V., <i>et al.</i> , "Evidence suggesting a role for hydroxyl radical in puromycin aminonucleoside-induced proteinuria", <i>Kidney International</i> , 34:494-499 (1988).
AS3	Nankivell, B.J., <i>et al.</i> , "The Role of Tubular Iron Accumulation in the Remnant Kidney", <i>J Am Soc Nephrol</i> , 4(8):1598-1607 (1994).
AT3	Alfrey, A.C., <i>et al.</i> , "Role of iron in the tubulo-interstitial injury in nephrotoxic serum nephritis", <i>Kidney International</i> , 36:753-759 (1989).
AU3	El Nahas, A.M., "Mechanisms of experimental and clinical renal scarring" In: "Oxford Textbook of Clinical Nephrology", 2 <sup>nd</sup> ed., pages 1749-1788, eds., Davidson, A.M., <i>et al.</i> , Oxford Univ. Press (1998).
AV3	Howard R.L., <i>et al.</i> , "Urinary albumin, transferrin and iron excretion in diabetic patients", <i>International Society of Nephrology</i> , 40:923-926 (1991).
AW3	Olivieri, N.F., <i>et al.</i> , "Iron-Chelation Therapy with Oral Deferiprone in Patients with Thalassemia Major", <i>The New England Journal of Medicine</i> , 918-922 (1995).
AX3	Alfrey A.C., "Toxicity of tubule fluid iron in the nephrotic syndrome", <i>American Journal of Physiology</i> , 263(4):F637-F641 (1992).
AY3	Wu,Z-L, <i>et al.</i> , "Iron Loading Enhances Susceptibility to Renal Ischemia in Rats," <i>Renal Failure</i> 16(4):471-480 (1994).

EXAMINER	DATE CONSIDERED
----------	-----------------

PTO-1449 REPRODUCED  <b>INFORMATION DISCLOSURE CITATION IN AN APPLICATION</b>  November 14, 2003  (Use several sheets if necessary)	ATTORNEY DOCKET NO. 2629.1003-010	DIVISIONAL APPLICATION NO. 09/553,496	
	APPLICANT Sudhir V. Shah		
	FILING DATE	CONFIRMATION NO.	GROUP
			1654

EXAMINER	DATE CONSIDERED
----------	-----------------